Sarepta rolls with eteplirsen NDA: new FDA relationship?
This article was originally published in Scrip
Executive Summary
Maybe it was having a new CEO that put Sarepta Therapeutics in a better light with the FDA, which finally gave the company the green light to move forward with its rolling new drug application (NDA) for its experimental Duchenne muscular dystrophy (DMD) drug eteplirsen.